Translational medicine from bedside to bench and back again: Methotrexate revisited

International Journal of Clinical Rheumatology

Volumn 8, Issue 2, 2013, Pages 291-306

  Ćalasan, Maja Bulatović ^a,b   Thurlings, Rogier M ^b,c   Wulffraat, Nico M ^a   Prakken, Berent J ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b EUREKA Institute for Translational Medicine   (Italy)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

adverse effect; biological; juvenile idiopathic arthritis; mechanism of action; methotrexate; registry; rheumatoid arthritis; tailor made therapy; translational medicine

Indexed keywords

ABATACEPT; ADALIMUMAB; AMINOPTERIN; AZATHIOPRINE; CERTOLIZUMAB PEGOL; ETANERCEPT; FOLIC ACID; GOLD COMPLEX; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; POLYGLUTAMIC ACID; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADJUVANT ARTHRITIS; ANEMIA; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CANCER RISK; CHILDHOOD LEUKEMIA; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DIGESTIVE SYSTEM ULCER; DISEASE ACTIVITY; DISEASE CONTROL; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EFFECTOR CELL; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS; PSORIATIC ARTHRITIS; REGULATORY T LYMPHOCYTE; REMISSION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; STOMATITIS;

EID: 84875715883     PISSN: 17584272     EISSN: 17584280     Source Type: Journal    
DOI: 10.2217/ijr.13.13     Document Type: Review

References (126)

1. Albani S, Prakken B. The advancement of translational medicine-from regional challenges to global solutions. Nat. Med. 15(9), 1006-1009 (2009)..
2. Pincus T, Cronstein B, Braun J. Methotrexate -the anchor drug -An introduction. Clin. Exp. Rheumatol. 28(5 Suppl. 61), S1-S2 (2010)..
3. Kavanaugh A, Fleischmann RM, Emery P et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann. Rheum. Dis. 72(1), 64-71 (2013)..
4. Wallace CA, Giannini EH, Spalding SJ et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 64(6), 2012-2021 (2012)..
5. Tynjälä P, Vahasalo P, Tarkiainen M et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann. Rheum. Dis. 70(9), 1605-1612 (2011)..
6. Hashkes PJ, Uziel Y, Laxer RM. The safety profile of biologic therapies for juvenile idiopathic arthritis. Nat. Rev. Rheumatol. 6(10), 561-571 (2010)..
7. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343(22), 1586-1593 (2000)..
8. Genovese MC, Bathon JM, Martin RW et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 46(6), 1443-1450 (2002)..
9. Emery P, Fleischmann RM, Moreland LW et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a Phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 60(8), 2272-2283 (2009)..
10. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410), 675-681 (2004)..
11. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54(1), 26-37 (2006)..
12. van der Heijde D, Klareskog L, Rodriguez-Valverde V et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 54(4), 1063-1074 (2006)..
13. Benedek TG. Methotrexate: from its introduction to non-oncologic therapeutics to anti-TNF-Alpha. Clin. Exp. Rheumatol. 28(5 Suppl. 61), S3-S8 (2010)..
14. Coury FF, Weinblatt ME. Clinical trials to establish methotrexate as a therapy for rheumatoid arthritis. Clin. Exp. Rheumatol. 28(5 Suppl. 61), S9-S12 (2010)..
15. Thompson RN, Watts C, Edelman J, Esdaile J, Russell AS. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J. Rheumatol. 11(6), 760-763 (1984)..
16. Weinblatt ME, Coblyn JS, Fox DA et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N. Engl. J. Med. 312(13), 818-822 (1985)..
17. Williams HJ, Willkens RF, Samuelson CO Jr et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 28(7), 721-730 (1985)..
18. Andersen PA, West SG, O'Dell JR, Via CS, Claypool RG, Kotzin BL. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann. Intern. Med. 103(4), 489-496 (1985)..
19. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69(6), 964-975 (2010)..
20. Truckenbrodt H, Hafner R. Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study. Arthritis Rheum. 29(6), 801-807 (1986)..
21. Woo P, Southwood TR, Prieur AM et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 43(8), 1849-1857 (2000)..
22. Giannini EH, Brewer EJ, Kuzmina N et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N. Engl. J. Med. 326(16), 1043-1049 (1992)..
23. Ruperto N, Murray KJ, Gerloni V et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 50(7), 2191-2201 (2004)..
24. Beukelman T, Patkar NM, Saag KG et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. (Hoboken) 63(4), 465-482 (2011)..
25. Maini R, St Clair EW, Breedveld F et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet 354(9194), 1932-1939 (1999)..
26. Keystone E, Heijde D, Mason D Jr et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 58(11), 3319-3329 (2008)..
27. Kremer JM, Genant HK, Moreland LW et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 144(12), 865-876 (2006)..
28. Cohen SB, Moreland LW, Cush JJ et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann. Rheum. Dis. 63(9), 1062-1068 (2004)..
29. Jones G, Sebba A, Gu J et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann. Rheum. Dis. 69(1), 88-96 (2010)..
30. van der Heijde D, Klareskog L, Landewe R et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 56(12), 3928-3939 (2007)..
31. Dougados M, Kissel K, Sheeran T et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann. Rheum. Dis. 72(1), 43-50 (2012)..
32. Ruperto N, Giannini EH, Pistorio A, Brunner HI, Martini A, Lovell DJ. Is it time to move to active comparator trials in juvenile idiopathic arthritis? A review of current study designs. Arthritis Rheum. 62(11), 3131-3139 (2010)..
33. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 377(9783), 2138-2149 (2011)..
34. Lovell DJ, Giannini EH, Reiff A et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 342(11), 763-769 (2000)..
35. Lovell DJ, Ruperto N, Goodman S et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med. 359(8), 810-820 (2008)..
36. Ruperto N, Lovell DJ, Quartier P et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372(9636), 383-391 (2008)..
37. Lovell DJ, Reiff A, Jones OY et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 54(6), 1987-1994 (2006)..
38. Ruperto N, Lovell DJ, Quartier P et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 62(6), 1792-1802 (2010).
39. Yokota S, Imagawa T, Mori M et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal Phase III trial. Lancet 371(9617), 998-1006 (2008)..
40. Quartier P, Allantaz F, Cimaz R et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 70(5), 747-754 (2011)..
41. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201(9), 1479-1486 (2005)..
42. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 40(7), 1202-1209 (1997)..
43. Verstappen SM, Jacobs JWG, van der Veen MJ et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann. Rheum. Dis. 66(11), 1443-1449 (2007)..
44. Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J. Rheumatol. 16(3), 313-320 (1989)..
45. Visser K, van der HD. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann. Rheum. Dis. 68(7), 1094-1099 (2009)..
46. Klein A, Kaul I, Foeldvari I, Ganser G, Urban A, Horneff G. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German Methotrexate Registry. Arthritis Care Res. (Hoboken) 64(9), 1349-1356 (2012)..
47. Braun J, Kastner P, Flaxenberg P et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, Phase IV trial. Arthritis Rheum. 58(1), 73-81 (2008)..
48. Hull RG. Guidelines for management of childhood arthritis. Rheumatology (Oxford) 40(11), 1309-1312 (2001)..
49. Hashkes PJ. Pediatric rheumatology: strengths and challenges of a new guide for treating JIA. Nat. Rev. Rheumatol. 7(7), 377-378 (2011)..
50. den Boer E, Meesters RJ, van Zelst BD et al. Measuring methotrexate polyglutamates in red blood cells: a new LC-MS/MS-based method. Anal. Bioanal. Chem. 405(5), 1673-1681 (2013)..
51. Davila L, Ranganathan P. Pharmacogenetics: implications for therapy in rheumatic diseases. Nat. Rev. Rheumatol. 7(9), 537-550 (2011)..
52. Albers HM, Wessels JA, van der Straaten RJ et al. Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. Arthritis Rheum. 61(1), 46-51 (2009)..
53. Yanagimachi M, Naruto T, Hara T et al. Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis. Br. J. Clin. Pharmacol. 71(2), 237-243 (2011)..
54. Becker ML, Gaedigk R, van Haandel L et al. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum. 63(1), 276-285 (2011)..
55. Tukova J, Chladek J, Hroch M, Nemcova D, Hoza J, Dolezalova P. 677TT genotype is associated with elevated risk of methotrexate (MTX) toxicity in juvenile idiopathic arthritis: treatment outcome, erythrocyte concentrations of MTX and folates, and MTHFR polymorphisms. J. Rheumatol. 37(10), 2180-2186 (2010)..
56. Hinks A, Moncrieffe H, Martin P et al. Association of the 5-Aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis. Ann. Rheum. Dis. 70(8), 1395-1400 (2011)..
57. Moncrieffe H, Hinks A, Ursu S et al. Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype. Pharmacogenet. Genomics 20(11), 665-676 (2010)..
58. Takatori R, Takahashi KA, Tokunaga D et al. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin. Exp. Rheumatol. 24(5), 546-554 (2006)..
59. Drozdzik M, Rudas T, Pawlik A et al. The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur. J. Clin. Pharmacol. 62(11), 933-937 (2006)..
60. de Rotte MC, Bulatovic M, Heijstek MW et al. ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis. J. Rheumatol. 39(10), 2032-2040 (2012)..
61. Bulatovic M, Heijstek MW, Van Dijkhuizen EH, Wulffraat NM, Pluijm SM, de Jonge R. Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis. Ann. Rheum. Dis. 71(9), 1484-1489 (2012)..
62. Wessels JA, van der Kooij SM, le Cessie S et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 56(6), 1765-1775 (2007)..
63. Toll DB, Janssen KJ, Vergouwe Y, Moons KG. Validation, updating and impact of clinical prediction rules: a review. J. Clin. Epidemiol. 61(11), 1085-1094 (2008)..
64. Reilly BM, Evans AT. Translating clinical research into clinical practice: impact of using prediction rules to make decisions. Ann. Intern. Med. 144(3), 201-209 (2006)..
65. Bulatovic M, Heijstek MW, Verkaaik M et al. High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Arthritis Rheum. 63(7), 2007-2013 (2011)..
66. Verstappen SM, Bakker MF, Heurkens AH et al. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann. Rheum. Dis. 69(6), 1044-1048 (2010)..
67. Beukelman T, Haynes K, Curtis JR et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 64(4), 1263-1271 (2012)..
68. de Kleer I, Wedderburn LR, Taams LS et al. CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J. Immunol. 172(10), 6435-6443 (2004)..
69. Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, Wedderburn LR. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum. 58(3), 875-887 (2008).
70. Nistala K, Adams S, Cambrook H et al. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc. Natl Acad. Sci. USA 107(33), 14751-14756 (2010)..
71. Ehrenstein MR, Evans JG, Singh A et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J. Exp. Med. 200(3), 277-285 (2004)..
72. Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 105(49), 19396-19401 (2008)..
73. Wehrens EJ, Mijnheer G, Duurland CL et al. Functional human regulatory T cells fail to control autoimmune inflammation due to PKB/c-Akt hyperactivation in effector cells. Blood 118(13), 3538-3548 (2011)..
74. Foell D, Wulffraat N, Wedderburn LR et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 303(13), 1266-1273 (2010)..
75. Hunt PG, Rose CD, Ilvain-Simpson G, Tejani S. The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study. J. Rheumatol. 24(11), 2230-2232 (1997)..
76. Ravelli A, Migliavacca D, Viola S, Ruperto N, Pistorio A, Martini A. Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 17(5), 625-627 (1999)..
77. Visser K, Katchamart W, Loza E et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann. Rheum. Dis. 68(7), 1086-1093 (2009)..
78. Ortiz Z, Shea B, Suarez AM, Moher D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst. Rev. (2), CD000951 (2000)..
79. Jansen G, van der Heijden J, Oerlemans R et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum. 50(7), 2130-2139 (2004)..
80. Chan ES, Cronstein BN. Methotrexate -how does it really work? Nat. Rev. Rheumatol. 6(3), 175-178 (2010)..
81. Assaraf YG. Molecular basis of antifolate resistance. Cancer Metastasis Rev. 26(1), 153-181 (2007)..
82. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-Aminoimidazole-4- carboxamide ribotide transformylase, adenosine deaminase and 5́-Adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-Aminoimidazole-4-carboxamide riboside and ribotide. Biochem. J. 236(1), 193-200 (1986)..
83. Montesinos MC, Takedachi M, Thompson LF, Wilder TF, Fernandez P, Cronstein BN. The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5́-nucleotidase: findings in a study of ecto-5́-nucleotidase gene-deficient mice. Arthritis Rheum. 56(5), 1440-1445 (2007)..
84. Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov. 7(9), 759-770 (2008)..
85. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Invest. 92(6), 2675-2682 (1993)..
86. Morabito L, Montesinos MC, Schreibman DM et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5́-nucleotidase-mediated conversion of adenine nucleotides. J. Clin. Invest. 101(2), 295-300 (1998)..
87. Montesinos MC, Desai A, Delano D et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum. 48(1), 240-247 (2003)..
88. Montesinos MC, Yap JS, Desai A, Posadas I, McCrary CT, Cronstein BN. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum. 43(3), 656-663 (2000)..
89. Baggott JE, Morgan SL, Sams WM, Linden J. Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis. Arch. Dermatol. 135(7), 813-817 (1999)..
90. Laghi PF, Capecchi PL, Di PT. Adenosine plasma levels after low dose methotrexate administration. J. Rheumatol. 24(12), 2492-2493 (1997)..
91. Smolenska Z, Kaznowska Z, Zarowny D, Simmonds HA, Smolenski RT. Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatoid arthritis. Rheumatology (Oxford) 38(10), 997-1002 (1999)..
92. Dolezalova P, Krijt J, Chladek J, Nemcova D, Hoza J. Adenosine and methotrexate polyglutamate concentrations in patients with juvenile arthritis. Rheumatology (Oxford) 44(1), 74-79 (2005)..
93. Borsellino G, Kleinewietfeld M, Di MD et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110(4), 1225-1232 (2007)..
94. Deaglio S, Dwyer KM, Gao W et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204(6), 1257-1265 (2007)..
95. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5́-Adenosine monophosphate to adenosine. J. Immunol. 177(10), 6780-6786 (2006)..
96. Ohta A, Kini R, Ohta A, Subramanian M, Madasu M, Sitkovsky M. The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front. Immunol. 3, 190 (2012)..
97. Zarek PE, Huang CT, Lutz ER et al. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111(1), 251-259 (2008)..
98. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J. Clin. Invest. 102(2), 322-328 (1998)..
99. Spurlock CF, Aune ZT, Tossberg JT et al. Increased sensitivity to apoptosis induced by methotrexate is mediated by JNK. Arthritis Rheum. 63(9), 2606-2616 (2011)..
100. Spurlock CF, Tossberg JT, Fuchs HA, Olsen NJ, Aune TM. Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum. 64(6), 1780-1789 (2012).
101. Phillips DC, Woollard KJ, Griffiths HR. The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br. J. Pharmacol. 138(3), 501-511 (2003)..
102. Fairbanks LD, Ruckemann K, Qiu Y et al. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis? Biochem. J. 342(Pt 1), 143-152 (1999)..
103. Hildner K, Finotto S, Becker C et al. Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis. Clin Exp. Immunol. 118(1), 137-146 (1999)..
104. Gerards AH, de Lathouder S, de Groot ER, Dijkmans BA, Aarden LA. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) 42(10), 1189-1196 (2003)..
105. Segal R, Mozes E, Yaron M, Tartakovsky B. The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum. 32(4), 370-377 (1989)..
106. Constantin A, Loubet-Lescoulie P, Lambert N et al. Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum. 41(1), 48-57 (1998)..
107. Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum. 50(5), 1370-1382 (2004)..
108. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol. Rev. 57(2), 163-172 (2005)..
109. Dervieux T, Furst D, Lein DO et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 50(9), 2766-2774 (2004)..
110. Dervieux T, Furst D, Lein DO et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann. Rheum. Dis. 64(8), 1180-1185 (2005)..
111. Koizumi S, Curt GA, Fine RL, Griffin JD, Chabner BA. Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. J. Clin. Invest. 75(3), 1008-1014 (1985)..
112. Chabner BA, Allegra CJ, Curt GA et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J. Clin. Invest. 76(3), 907-912 (1985)..
113. Kremer JM, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum. 29(7), 832-835 (1986)..
114. Dalrymple JM, Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Barclay ML. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 58(11), 3299-3308 (2008)..
115. Rudwaleit M, Yin Z, Siegert S et al. Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4. Ann. Rheum. Dis. 59(4), 311-314 (2000)..
116. Seitz M, Zwicker M, Wider B. Enhanced in vitro induced production of interleukin 10 by peripheral blood mononuclear cells in rheumatoid arthritis is associated with clinical response to methotrexate treatment. J. Rheumatol. 28(3), 496-501 (2001)..
117. Lina C, Conghua W, Nan L, Ping Z. Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis. J. Clin. Immunol. 31(4), 596-605 (2011)..
118. Kraan MC, Smeets TJ, van Loon MJ, Breedveld FC, Dijkmans BA, Tak PP. Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Ann. Rheum. Dis. 63(9), 1056-1061 (2004)..
119. Crilly A, McInness IB, McDonald AG, Watson J, Capell HA, Madhok R. Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate. J. Rheumatol. 22(2), 224-226 (1995)..
120. Dolhain RJ, Tak PP, Dijkmans BA, De Kuiper P., Breedveld FC, Miltenburg AM. Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br. J. Rheumatol. 37(5), 502-508 (1998)..
121. Kraan MC, Reece RJ, Barg EC et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum. 43(8), 1820-1830 (2000)..
122. van den Ham HJ, de Jager W, Bijlsma JW, Prakken BJ, de Boer RJ. Differential cytokine profiles in juvenile idiopathic arthritis subtypes revealed by cluster analysis. Rheumatology (Oxford) 48(8), 899-905 (2009)..
123. de Jager W, Vastert SJ, Beekman JM et al. Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 60(9), 2782-2793 (2009)..
124. de Jager W, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann. Rheum. Dis. 66(5), 589-598 (2007)..
125. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum. 50(12), 3762-3771 (2004)..
126. Frosch M, Ahlmann M, Vogl T et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 60(3), 883-891 (2009)..